Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Bay LB, Denzler I, Durand C, Eiroa H, Frabasil J, Fainboim A, Maxit C, Schenone A, Spécola N (2019) Infantile-onset pompe disease: diagnosis and management. Arch Argent Pediatr 117:271–278
Cuker A, Neunert CE (2016) How I treat refractory immune thrombocytopenia. Blood 128:1547–1554
Côté A, Keating B (2012) What is wrong with orphan drug policies? Value Health 15:1185–1191
Das AM (2017) Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1). Appl Clin Genet 10:43–48
Deutscher Ethikrat (2018) Herausforderungen im Umgang mit seltenen Erkrankungen. https://www.ethikrat.org/fileadmin/Publikationen/Ad-hoc-Empfehlungen/deutsch/herausforderungen-im-umgang-mit-seltenen-erkrankungen.pdf
Dupont AG, Van Wilder PB (2011) Access to orphan drugs despite poor quality of clinical evidence. Br J Clin Pharmacol 71:488–496
El-Abassi R, Singhal D, England JD (2014) Fabry’s disease. J Neurol Sci 344:5–19
Europäische Kommission (2018) Verordnung (EU) 2018/781 der Kommission vom 29. Mai 2018 zur Änderung der Verordnung (EG) Nr. 847/2000 in Bezug auf die Bestimmung des Begriffs „ähnliches Arzneimittel“. https://eur-lex.europa.eu/legal-content/DE/TXT/PDF/?uri=CELEX:32018R0781&from=DE
Europäisches Parlament und Rat (2000) Verordnung (EG) Nr. 141/2000 des Europäischen Parlaments und des Rates vom 16. Dezember 1999 über Arzneimittel für seltene Leiden. Amtsblatt der Europäischen Gemeinschaften L18/1 vom 22.1.2000. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:DE:PDF
European Commission (2016) Inventory of union and member state incentives to support research into, and the development and availability of, orphan medicinal products: State of play 2015. http://ec.europa.eu/health//sites/health/files/files/orphanmp/doc/orphan_inv_report20160126.pdf
European Medicines Agency (EMA) (2017) Conditional marketing authorisation: report on ten years of experience at the European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2017/01/WC500219991.pdf
European Medicines Agency (2018) Annual report 2018. https://www.ema.europa.eu/en/news/ema-annual-report-2018-published
European Social Insurance Platform (2019) Review of regulation (EC) No 141/200 on orphan medicinal products (OMP). https://esip.eu/publications-intranet?idf=222&preview=572
Evaluate Pharma (2019) Orphan Drug Report 2019, 6. Auflage. https://www.evaluate.com/thought-leadership/pharma/evaluatepharma-orphan-drug-report-2019
Gammie T, Lu CY, Ud-Din Babar Z (2015) Access to orphan drugs: a comprehensive review of Legislations, regulations and policies in 35 countries. PLoS ONE 10(10):e0140002
Gemeinsamer Bundesausschuss (2011): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über die Einfügung eines Kapitels zur Bewertung des Nutzens von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) in die Verfahrensordnung. Vom 20. Januar 2011. BAnz 2000; 63 (Nummer 95a): 3–78
Giannuzzi V, Landi A, Bosone E et al (2017) Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorization failures and abandoned drugs. BMJ Open 7:e17358
Gottwald S, Huster S (2013) Personalisierte Medizin als Orphanisierung: rechtliche und ethische Fragen. Ethik Med 25:259–266
Haffner ME, Torrent-Farnell J, Maher PD (2008) Does orphan drug legislation really answer the needs of patients? Lancet 371:2041–2044
Hochhaus A, Eigendorff E, Ernst T (2018) Chronische Myeloische Leukämie. Dtsch med Wochenschr 143:1304–1310
Hofer MP, Hedman H, Mavris et al (2018) Marketing authorization of orphan medicines in Europe from 2000 to 2013. Drug Discovery Today 23:424–433
Jabbour E, Kantarjian H (2018) Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol 93:442–459
Jabbour E, O’Brein S, Ravandi F, Kantarjian H (2015) Monoclonal antibodies in acute lymphoblastic leukemia. Blood 26:4010–4016
Joppi R, Bertele V, Garattini S (2013) Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol 69:1009–1024
Joppi R, Gerardi C, Bertele V, Garattini S (2016) Letting post-marketing bridge the evidence gap: the case of orphan drugs. BMJ 353:i2978
Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gökbuget N, O’Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS (2016) Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375:740–753
Kesselheim AS, Myers JA, Avorn J (2011) Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA 305:2320–2326
Kesselheim AS, Treasure CL, Joffe S (2017) Biomarker-defines subsets of common diseases: policy and economic implications of orphan drug act coverage. PLoS Med 14(1):e1002190
Kinch MS, Griesenauer RH (2019) 2018 in review: FDA approvals of new molecular entities. Drug Discov Today. https://doi.org/10.1016/j.drudis.2019.05.022
Lederer DJ, Martinez FJ (2018) Idiopathic pulmonary fibrosis. N Engl J Med 379:797–798
Ludwig W-D (2018) Zulassungsverfahren für neue Arzneimittel in Europa. In: Schwabe U, Paffrath D, Ludwig W-D, Klauber J (Hrsg) Arzneiverordnungs-Report 2018. Springer, Berlin, Heidelberg, S 27–51
Ludwig W-D (2019) Orphan Drugs aus Sicht der Arzneimittelkommission der deutschen Ärzteschaft. Internist 60:399–404
Mastellos DC, Reis ES, Yancopoulou D, Risitano AM, Lambris JD (2018) Expanding complement therapeutics for the treatment of paroxysmal nocturnal hemoglobinuria. Semin Hematol 55:167–175
Matzdorff A, Wörmann B (2018) Diagnostik und Therapie der Immunthrombozytopenie. Dtsch med Wochenschr 143:1076–1081
McCafferty EH, Scott LJ (2019) Migalastat: a review in Fabry disease. Drugs 79:543–554
Melnikova I (2012) Rare diseases and orphan drugs. Nature Rev Drug Discov 11:267–268
Mitsumoto J, Dorsey ER, Beck CA et al (2009) Pivotal studies of orphan drugs approved for neurological diseases. Ann Neurol 66:184–190 (https://www.orpha.net/orphacom/cahiers/docs/DE/Pravalenzen_seltener_Krankheiten_absteigender_Pravalenz_oder_Falle.pdf)
Morris AA, Kožich V, Santra S, Andria G, Ben-Omran TI, Chakrapani AB, Crushell E, Henderson MJ, Hochuli M, Huemer M, Janssen MC, Maillot F, Mayne PD, McNulty J, Morrison TM, Ogier H, O’Sullivan S, Pavlíková M, de Almeida IT, Terry A, Yap S, Blom HJ, Chapman KA (2017) Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. J Inherit Metab Dis 40:49–74
Mullard A (2019) 2018 FDA drug approvals. Nat Rev Drug Discov 18:85–89
Naehrig S, Chao CM, Naehrlich L (2017) Cystic fibrosis – diagnosis and treatment. Dtsch Arztebl Int 114:564–574
Orphan Drug Act (1983) An act to amend the federal food, drug, and cosmetic act to facilitate the development of drugs for rare diseases and conditions, and for other purposes. 97th Congress. (http://history.nih.gov/research/downloads/PL97-414.pdf)
Parini R, Deodato F, Di Rocco M, Lanino E, Locatelli F, Messina C, Rovelli A, Scarpa M (2017) Open issues in mucopolysaccharidosis type I-Hurler. Orphanet J Rare Dis 12:112. https://doi.org/10.1186/s13023-017-0662-9
Raza S, Safyan RA, Rosenbaum E, Bowman AS, Lentzsch S (2017) Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist. Ther Adv Hematol 8:55–70
Roll K, Stargardt T, Schreyogg J (2011) Zulassung und Erstattung von Orphan Drugs im internationalen Vergleich. Gesundheitswesen 73:504–514
Sarpatwari A, Kesselheim AS (2019) Reforming the orphan drug Act for the 21st century. N Engl J Med 381:106–108
Schieppati A, Henter JI, Daina E, Aperia A (2008) Why rare diseases are an important medical and social issue. Lancet 371:2039–2041
Shanmuganathan N, Hughes TP (2018) Molecular monitoring in CML: how deep? How often? How should it influence therapy? Blood 132:2125–2133
Simon S, Resch H, Klaushofer K, Roschger P, Zwerina J, Kocijan R (2018) Hypophosphatasia: from diagnosis to treatment. Curr Rheumatol Rep 20:69. https://doi.org/10.1007/s11926-018-0778-5
Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, Levade T, Astudillo L, Serratrice J, Brassier A, Rose C, Billette de Villemeur T, Berger MG (2017) A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci 18(2):E441. https://doi.org/10.3390/ijms18020441
Stone RM, Manley PW, Larson RA, Capdeville R (2018) Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv 2:444–453
Sträter B, Burgardt C, Bickmann M (2014) Arzneimittel für seltene Leiden – Situation in der Europäischen Union. Arzneim Recht Ausg 5:195–201
Sydow S, Throm S (2019) Orphan Drugs aus Sicht der forschenden Pharma- und Biotech-Firmen. Internist 60:405–410
Taher AT, Weatherall DJ, Cappellini MD (2018) Thalassaemia. Lancet 391:155–167
Tay-Teo K, Ilbawi A, Hill SR (2019) Comparison sales income and research and development costs for FDA-approved cancer drugs sold by originator drug companies. JAMA Netw Open 2(1):e186875
The Committee for Orphan Medicinal Products and the European Medicines Agency Scientific Secretariat (2011) European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat Rev Drug Discov 10:341–349
Thenappan T, Ormiston ML, Ryan JJ, Archer SL (2018) Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ 360:j5492. https://doi.org/10.1136/bmj.j5492
von Tresckow J, Eichhorst B, Bahlo J, Hallek M (2019) Behandlung der chronischen lymphatischen Leukämie. Dtsch Ärztebl 116:41–46
Voigt B (2015) Lukratives Geschäft mit seltenen Krankheiten. Neue Zürcher Zeitung. http://www.nzz.ch/nzzas/nzzam-sonntag/lukratives-geschaeft-mit-seltenen-krankheiten-1.18534575. Zugegriffen: 14. Aug. 2017
Waisbren SE, Gropman AL, Members of the Urea Cycle Disorders Consortium (UCDC), Batshaw ML (2016) Improving long term outcomes in urea cycle disorders-report from the Urea Cycle Disorders Consortium. J Inherit Metab Dis 39:573–584
van Wegberg AMJ, MacDonald A, Ahring K, Bélanger-Quintana A, Blau N, Bosch AM, Burlina A, Campistol J, Feillet F, Giżewska M, Huijbregts SC, Kearney S, Leuzzi V, Maillot F, Muntau AC, van Rijn M, Trefz F, Walter JH, van Spronsen FJ (2017) The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis 12:162. https://doi.org/10.1186/s13023-017-0685-2
Whiteman DA, Kimura A (2017) Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future. Drug Des Devel Ther 11:2467–2480
Windeler J, Koch K, Lange S, Ludwig WD (2010) Zu guter Letzt ist alles selten. Dtsch Arztebl 107:A2032–A2034
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Ludwig, WD., Schwabe, U. (2019). Orphan-Arzneimittel. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2019. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-59046-1_5
Download citation
DOI: https://doi.org/10.1007/978-3-662-59046-1_5
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-59045-4
Online ISBN: 978-3-662-59046-1
eBook Packages: Medicine (German Language)